Cytokinetics EVP Fady Malik sells $214,830 in company stock
Cytokinetics (CYTK) EVP Fady Malik sold 3,500 shares for $214,830 at $61.38 each, holding 153,902 shares. He also exercised options for 3,500 shares at $7.8 each. CYTK, valued at $8.75B, reported $25.3M in Myqorzo sales, beating estimates. Analysts have strong buy consensus with targets up to $146. The company faces legal action against Bristol-Myers and MyoKardia.
How this was made
The 30-second read
Why it matters
Insider activity may temporarily affect stock price despite positive fundamentals.
Market read
The insider sale is the primary new fact; broader company news is already known.
What to watch
The simultaneous option exercise at a low price may indicate confidence in long‑term upside.
Background
Cytokinetics reported strong Q2 sales of Myqorzo and raised price targets, but the article focuses on an insider transaction.
Ticker impact
EVP of R&D sold 3,500 shares for $214,830 and bought 3,500 shares via options, indicating insider activity.
likely pressure as the market prices in the insider sell
Insider sales, even modest, can signal lack of confidence and trigger sell‑offs.
Market effects
Minimal impact on biotech sector beyond the specific insider activity.
None
Low
Counterpoint
The sale could be a routine diversification rather than a negative signal.
Key entities
- ExecutiveFady Ibraham Malik
Executive Vice President of R&D at Cytokinetics
